Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 2 Study of Mitoxantrone, Etoposide, and Cytarabine (MEC) Plus Lenalidomide for the Treatment of Adult Patients With Relapsed or Refractory Acute Myeloid Leukemia

Next Previous
X
Search
Trial Profile

Phase 2 Study of Mitoxantrone, Etoposide, and Cytarabine (MEC) Plus Lenalidomide for the Treatment of Adult Patients With Relapsed or Refractory Acute Myeloid Leukemia

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 26 Apr 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Lenalidomide (Primary) ; Cytarabine; Etoposide; Mitoxantrone
  • Indications Acute biphenotypic leukaemia; Acute myeloid leukaemia
  • Focus Therapeutic Use

    • Most Recent Events

    • 22 Apr 2024 Status changed from active, no longer recruiting to completed.
    • 12 Dec 2023 Results assessing efficacy of mitoxantrone, etoposide, and Cytarabine (MEC),and Lenalidomide (Len) combination,presented at the 65th American Society of Hematology Annual Meeting and Exposition
    • 13 Jan 2021 Planned End Date changed from 30 Sep 2024 to 1 Aug 2021.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top